Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock

Intensive Care Medicine

Volumn 22, Issue 9, 1996, Pages 888-893

  Staudinger, T ^a   Presterl, E ^a   Graninger, W ^a   Locker, G J ^a   Knapp, S ^a   Laczika, K ^a   Klappacher, G ^a   Stoiser, B ^a   Wagner, A ^a   Tesinsky, P ^a   Kordova, H ^a   Frass, M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cytokines; Pentoxifylline; Septic shock

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CYTOKINE; FIBRONECTIN; HAPTOGLOBIN; INTERLEUKIN 6; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INDEX; HEMODYNAMIC PARAMETERS; HUMAN; INTENSIVE CARE; MALE; SEPTIC SHOCK; SYSTEMIC VASCULAR RESISTANCE;

EID: 10244232899     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02044112     Document Type: Article

References (47)

1. Moldawer LL (1994) Biology of proinflammatory cytokines and their antagonists. Crit Care Med 22:S3-S7
2. Bone RC (1994) Sepsis and its complications: the clinical problem. Crit Care Med 22:S8-S11
3. Bellomo R (1992) The cytokine network in the critically ill. Anaesth Intensive Care 20:288-302
4. Parrillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328:1471-1477
5. Suffredini AF (1994) Current prospects for the treatment of clinical sepsis. Crit Care Med 22:S12-S18
6. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110:192-198
7. Beutler B, Grau GE (1993) Tumor necrosis factor in the pathogenesis of infectious disease. Crit Care Med 21:S423-S435
8. Mackay J, Boyd OF, Henderson S, Bennett ED (1992) Pentoxifylline causes a dose dependent reduction in mortality in patients with sepsis syndrome (abstract). Clin Sci 82:33P
9. Mayer N, Steltzer H, Klimscha W, Oismueller C, Hammerle AF (1991) Cardiorespiratory effects of pentoxifylline in septic and non-septic states (abstract). Anesthesiology 75:A232
10. Harada H, Ishizaka A, Yonemaru M, Mallick AA, Hatherill JR, Zheng H (1989) The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis 140:974-980
11. Noel P, Nelson S, Bokulic R, Bagby G, Lippton H, Lipscomb G (1990) Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and positively influences mortality. Life Sci 47:1023-1029
12. Schade UF (1990) Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 31: 171-181
13. Barraso-Aranda J, Schmit-Schoenbein GW (1990) Pentoxifylline pretreatment decreases neutrophil activation during endotoxin shock and improves survival. In: Hakim J, Mandell GL, Novick WJ (ed) Pentoxifylline and analogues: effects on leukocyte function. Karger, Basel, pp 86-90
14. Law WR, Nadkarni VM, Fletcher MA, Nevola JJ, Eckstein JM, Quance J (1992) Pentoxifylline treatment of sepsis in conscious Yucatan minipigs. Circ Shock 37:291-300
15. Sarma PSA (1990) Pentoxifylline in septic shock. Postgrad Med J 66: 980-981
16. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17:389-393
17. Sullivan GW, Carper HT, Novick WJ, Mandell GL (1988) Pentoxifylline inhibits the inflammatory effects of endotoxin and endotoxin-induced cytokines on neutrophil function. In: Mandell GL, Novick WJ (eds) Pentoxifylline and leukocyte function. Hoechst-Roussel, Sommerville, pp 37-48
18. Rao KMK, Padmanabhan J, Cohen HJ, Curris MS (1990) Effect of pentoxifylline and analogs on actin state and cell surface receptor expression in human leukocytes. In: Hakim J, Mandell GL, Novick WJ (eds) Pentoxifylline and analogues: effects on leukocyte function. Karger, Basel, pp 64-70
19. Barroso-Aranda J, Schmid-Schoenbein GW (1990) Pentoxifylline pretreatment decrease the pool of activated neutrophils, in-vivo adhesion to endothelium, and improves survival from hemorrhagic shock. Biorheology 27:401-418
20. Sourbier P, Perianin A, Hakim J (1988) In vitro effects of pentoxifylline on human neutrophil function. In: Mandell GL, Novick WJ (eds) Pentoxifylline and leukocyte function. Hoechst-Roussel-Sommerville, pp 56-67
21. Slater K, Wiseman MS, Shale DJ, Fletcher J (1988) The effect of pentoxifylline on neutrophil function in vitro and ex vivo in human volunteers. In: Mandell GL, Novick WJ (eds) Pentoxifylline and leukocyte function. Hochest-Roussel, Sommerville, pp 115-123
22. Kumar KV, Das UN, Kumar GS, Das NP, Tan BK (1992) Effect of pentoxifylline on freed radical generation in human peripheral leukocytes. Asia Pac J Pharmacol 7:89-93
23. Beutler B (1990) Cachectin/tumor necrosis factor and lymphotoxin. In: Sporn MB, Roberts AB (eds) Handbook of experimental pharmacology: peptide growth factors and their receptors II. Springer, Berlin Heidelberg New York, pp 39-70
24. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474
25. Tracey KJ, Lowry SF, Fahey TJ, Albert JD, Fong Y, Hesse D, Beutler B, Manogue KR, Calvano S, Wei H (1987) Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 164:415-442
26. Tighe D, Moss R, Heath MF, Hynd J, Bennet ED (1989) Pentoxifylline reduces pulmonary leucostasis and improves capillary patency in a rabbit peritonitis model. Circ Shock 28:159-164
27. Tighe D, Moss R, Hynd J, Boghossian S, Al Saady N, Heath MF (1990) Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit Care Med 18:184-189
28. Zabel P, Wolter DT, Schoenharting MM, Schade UF (1989) Oxpentifylline in endotoxaemia. Lancet 334: 1474-1477
29. Beutler BA, Milsark IW, Cerami A (1985) Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 135: 3972-3977
30. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Chest 103:565-575
31. Pfizenmaier K, Himmler A, Schutze S (1993) TNF receptors and TNF signal transduction. In: Beutler B (ed) Tumor necrosis factors: the molecules and their emerging roles in medicine. Raven, New York, pp 439-472
32. Higuch M, Aggarwal BB (1992) Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P60 and P80 receptors. Biochem Biophys Res Commun 182: 638-643
33. Spinas GA, Keller U, Brockhaus M (1992) Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 90: 533-536
34. Porteu F, Nathan C (1990) Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172:599-607
35. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329
36. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutics agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151: 1548-1561
37. De Boer JP, Wolbink GJ, Thijs LG, Baars JW, Wagstaff J, Hack CE (1992) Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology 24:135-148
38. Waage A, Sorensen M, Fladvad Stordal B (1990) Effects of pentoxifylline and HWA 138 on production of tumor necrosis factor and interleukin 6 from monocytes. In: Hakim J, Mandell GL, Novick WJ (eds) Pentoxifylline and analogues: effects on leukocyte function. Karger, Basel, pp 86-90
39. Zabel P, Schoenharting MM, Schade UF, Schlaak M (1991) Effects of pentoxifylline in endotoxinemia in human volunteers. Prog Clin Biol Res 367: 207-213
40. Schade UF (1989) The role of prostacyclin in the protective effects of pentoxifylline and other xanthine derivatives in endotoxin action in mice. Eicosanoids 2:183-188
41. Sinzinger H (1983) Pentoxifylline enhances formation of prostacyclin from rat vascular and renal tissue. Prostaglandin Leukocyte Med 12:217-226
42. Lefer AM, Lefer DJ (1993) Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 33:71-90
43. Kainoh M, Imai R, Umetsu T, Hattori M, Nishio S (1990) Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 39:477-484
44. Simpson PJ, Mitsos SE, Ventura A, Gallagher KP, Fantone JC, Abrams GD, Schork MA, Lucchesi BR (1987) Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 113:129-137
45. Zabel P, Schade U (1993) Therapiestrategien gegen Mediatoren beim septischen Schock. Immun Infekt 21: 45-50
46. Roberts PJ, Yong KL, Khawa A, Johnson BV, Pizzey AR, Carver JE, Addison IE, Linch DC (1993) Pentoxyifylline at clinically achievable levels inhibits FMLP-induced neutrophil responses, but not priming, uregulation of cell-adhesion molecules, or migration induced by GM-CSF. Eur J Hematol 50:1-10
47. Endres S, Fülle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC (1991) Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells Immunology 72:56-60